Pharmacologic therapy for inflammatory bowel disease refractory to steroids

References

• D’HaensGRPannacioneRHigginsPThe London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug choose, and how to predict response?Am J Gastroenterol201110619921221045814
   PubMed Web of Science ®Google Scholar
• RutgeertsPDiamondRHBalaMScheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s diseaseGastrointest Endosc20066343344216500392
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet20023591541154912047962
   PubMed Web of Science ®Google Scholar
• BaertFMoortgatLvan AsscheGBelgian Inflammatory Bowel Disease Research GroupNorth-Holland Gut ClubMucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s diseaseGastroenterology201013846346819818785
   PubMed Web of Science ®Google Scholar
• ZallotCPeyrin-BirouletDeep remission in inflammatory bowel disease: looking beyond symptomsCurr Gastroenterol Rep20131531532223354742
   PubMedGoogle Scholar
• ParienteBCosnesJDaneseSDevelopment of the Crohn’s disease digestive damage score, The Lémann scoreInflamm Bowel Dis2011171415142221560202
   PubMed Web of Science ®Google Scholar
• OrdásIFeaganBGSandbornWJEarly use of immunosuppressive or TNF antagonists for the treatment of Crohn’s disease: time for a changeGut2011601754176321997558
   PubMed Web of Science ®Google Scholar
• FaubionWAJrLoftusEVJrHarmsenWSZinsmeisterARSandbornWJThe natural history of corticosteroid therapy for inflammatory bowel disease: a population-based studyGastroenterology200112125526011487534
   PubMed Web of Science ®Google Scholar
• DignassAVan AsscheGLindsayJOEuropean Crohn’s and Colitis Organisation (ECCO)The Second European evidence-based consensus on the diagnosis and management of Crohn’s disease. Current managementJ Crohns Colitis20104286221122489
   PubMed Web of Science ®Google Scholar
• DignassALindsayJSturmASecond European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementJ Crohns Colitis20126991103023040451
   PubMed Web of Science ®Google Scholar
• BärFSinaCFellermannKThiopurines in inflammatory bowel diseaseWorld J Gastroenterol2013191699170623555158
   PubMed Web of Science ®Google Scholar
• ChandeNTsoulisDJMacDonaldJKAzathioprine or 6-mercaptopurine for induction of remission in Crohn’s diseaseCochrane Database Syst Rev20134CD00054523633304
   PubMed Web of Science ®Google Scholar
• KhanKJDubinskyMCFordACEfficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysisAm J Gastroenterol201110663064221407186
   PubMed Web of Science ®Google Scholar
• ChatuSSubramanianVSaxenaSPollokRCThe role of thiopurines in reducing the need for surgical resection in Crohn’s diseaseAm J Gastroenterol2014109233424322839
   PubMed Web of Science ®Google Scholar
• D’HaensGGeboesKRutgeertsPEndoscopic and histologic healing of Crohn’s ileo- colitis with azathioprineGastrointest Endosc19995066767110536324
   PubMed Web of Science ®Google Scholar
• NielsenOHCoskunMSteenholdtCRoglerGThe role and advances of immunomodulator therapy for inflammatory bowel diseaseExpert Rev Gastroenterol Hepatol2015917718925101818
   PubMed Web of Science ®Google Scholar
• TimmerAMcDonaldJWTsoulisDIMacDonaldJKAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitisCochrane Database Syst Rev20129CD00047822972046
   PubMed Web of Science ®Google Scholar
• GisbertJPLinaresPMMcNichollAGMateJGomollónFMeta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitisAliment Pharmacol Ther20093012613719392869
   PubMed Web of Science ®Google Scholar
• ChhayaVSaxenaSCecilEThe impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989–2009Aliment Pharmacol Ther201541879825382737
   PubMed Web of Science ®Google Scholar
• ChaparroMOrdásICabreESafety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patientsInflamm Bowel Dis2013191404141023665964
   PubMed Web of Science ®Google Scholar
• RahierJFMagroFAbreuCSecond European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. European Crohn’s and Colitis Organization (ECCO)J Crohns Colitis2014844346824613021
   PubMed Web of Science ®Google Scholar
• KotlyarDSLewisJDBeaugerieLRisk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine: a meta-analysisClin Gastroenterol Hepatol201513847858.e424879926
   PubMed Web of Science ®Google Scholar
• DulaiPSSiegelCAColombelJFSandbornWPeyrin-BirouletLSystematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBDGut2014631843185324970900
   PubMed Web of Science ®Google Scholar
• BeaugerieLImmunosuppression-related lymphomas and cancers in IBD: how can they be prevented?Dig Dis20123041541922796808
   PubMed Web of Science ®Google Scholar
• LouisEIrvingPBeaugerieLUse of azathioprine in IBD: modern aspects of and old drugGut2014631695169924943205
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWSONIC Study GroupInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med20103621383139520393175
   PubMed Web of Science ®Google Scholar
• KennedyNAKallaRWarnerBThiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsAliment Pharmacol Ther2014401313132325284134
   PubMed Web of Science ®Google Scholar
• BryantRVBrainOTravisSPConventional drug therapy for inflammatory bowel diseaseScand J Gastroenterol2015509011225523560
   PubMed Web of Science ®Google Scholar
• SwaminathATaunkRJLawlorGUse of methotrexate in inflammatory bowel disease in 2014: a user’s guideWorld J Gastrointest Pharmacol Ther2014511312125133040
   PubMedGoogle Scholar
• McDonaldJWWangYTsoulisDJMcDonaldJKFeaganBGMethotrexate for induction of remission in refractory Crohn’s diseaseCochrane Database Syst Rev20146CD00345925099640
   PubMedGoogle Scholar
• PatelVWangYMcDonaldJKMcDonaldJWChandeNMethotrexate for maintenance of remission in Crohn’s diseaseCochrane Database Syst Rev20148CD00688425157445
   PubMed Web of Science ®Google Scholar
• ArdizzoneSBollaniSManzionnaGComparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomized, investigator-blind studyDig Liver Dis20033561962714563183
   PubMedGoogle Scholar
• McleanLPCrossRKAdverse events in IBD: to stop or continue immune suppressant and biological treatmentExpert Rev Gastroenterol Hepatol2014822324024490595
   PubMed Web of Science ®Google Scholar
• FeaganBGMcDonaldJWPannacioneRMethotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s diseaseGastroenterology201414668168824269926
   PubMed Web of Science ®Google Scholar
• FarkasKMolnárTSzepesZAbility of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitisExpert Rev Gastroenterol Hepatol2014869570224738535
   PubMed Web of Science ®Google Scholar
• NelsonRLiaoCFicheraAPekowJRescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitisInflamm Bowel Dis201420142024297054
   PubMed Web of Science ®Google Scholar
• ChangKHBurkeJPCoffeyJCInfliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysisInt J Colorectal Dis20132828729323114475
   PubMed Web of Science ®Google Scholar
• McDonaldJWFeaganBGJewellDBrynskowJStangeEFMcDonaldJKCyclosporine for induction of remission in Crohn’s diseaseCochrane Database Syst Rev20052CD00029715846602
   PubMedGoogle Scholar
• McSharryKDalzellAMLeiperKEl-MataryWSystematic review: the role of tacrolimus in the management of Crohn’s diseaseAliment Pharmacol Ther2011341282129421999607
   PubMed Web of Science ®Google Scholar
• SmithMRCooperSCMycophenolate mofetil therapy in the management of inflammatory bowel disease: a retrospective case series and reviewJ Crohns Colitis2014889089724507162
   PubMed Web of Science ®Google Scholar
• GerichMEYoonJLTarganSRIppoltiAFVasiliauskasEALong-term outcomes of thalidomide in refractory Crohn’s diseaseAliment Pharmacol Ther20154142943725511905
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med200435087688514985485
   PubMed Web of Science ®Google Scholar
• LichtensteinGRYanSBalaMBlankMSandsBEInfliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s diseaseGastroenterology2005128826829
   Web of Science ®Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology200613032333316472588
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenance treatment of Crohn’s disease: results of CLASSIC II trialGut2007561232123917299059
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: CHARM trialGastroenterology2007132526517241859
   PubMed Web of Science ®Google Scholar
• ColombelJFRutgeertsPSandbornWJDeep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: results from EXTENDJ Crohns Colitis2010138S158
   Google Scholar
• SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn’s previously treated with infliximab: a randomized trialAnn Intern Med200714682983817470824
   PubMed Web of Science ®Google Scholar
• SchreiberSCertolizumab pegol for the treatment of Crohn’s diseaseTherap Adv Gastroenterol20114375389
   PubMedGoogle Scholar
• DaWZhuJWangLLuYEfficacy and safety of certolizumab pegol from Crohn’s disease: a systematic review and meta-analysisAdv Ther20133054155323681504
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s diseaseAliment Pharmacol Ther2014391349136224749763
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353246276
   Web of Science ®Google Scholar
• LawsonMMThomasAGAkobengAKTumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitisCochrane Database Syst Rev20063CD00511216856078
   PubMedGoogle Scholar
• JärnerotGHertevigEFriis-LibyIInfliximab as rescue therapy in severe ulcerative colitis: a randomized, placebo-controlled studyGastroenterology20051281805181115940615
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severe active ulcerative colitis: results of randomized controlled trialGut20116078078721209123
   PubMed Web of Science ®Google Scholar
• SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe active ulcerative colitisGastroenterology201214225726522062358
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCPURSUIT-SC Study GroupSubcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisGastroenterology2014146859523735746
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCPURSUIT-Maintenance Study GroupSubcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisGastroenterology20141469610923770005
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPFeaganBGColectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabGastroenterology20091371250126019596014
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitisAliment Pharmacol Ther20143966067124506179
   PubMed Web of Science ®Google Scholar
• DaneseSFiorinoGPeyrin-BirouletLBiological agents for moderately to severe active ulcerative colitis. A systematic review and network meta-analysisAnn Intern Med201416070471124842416
   PubMed Web of Science ®Google Scholar
• PanaccioneRGoshSMiddletonSCombination therapy with infliximab and azathioprine is superior to monotherapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitisGastroenterology2014146392400.e324512909
   PubMed Web of Science ®Google Scholar
• Rinaudo-GaujousMPaulSTedescoEDGeninCRoblinSPeyrin-BirouletLReview article: are the next generation of drugs for liver and gastrointestinal diseaseAliment Pharmacol Ther20133891492424001128
   PubMed Web of Science ®Google Scholar
• DaneseSGomollonFGoverning Board and Operational Board of ECCOThe use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)J Crohns Colitis2013758658923623738
   PubMed Web of Science ®Google Scholar
• SeowCHNewmanAIrwinSSteinhartASilverbergMGreenbergGTrough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut201059495419651627
   PubMed Web of Science ®Google Scholar
• ChiuILRubinDTVermiereSSerum adalimumab concentration and clinical remission in patients with Crohn’s diseaseInflamm Bowel Dis2013191112112223584130
   PubMed Web of Science ®Google Scholar
• KopylovUBen-HorinSSeidmanETherapeutic drug monitoring in inflammatory bowel diseaseAnn Gastroenterol20142730431225331715
   PubMedGoogle Scholar
• Ben-HorinSKopylovUChowersYOptimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmun Rev201413243023792214
   PubMed Web of Science ®Google Scholar
• PapamichaelKGilsARutgeertsPRole for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponseInflamm Bowel Dis20152118219725222660
   PubMed Web of Science ®Google Scholar
• LichtensteinGRFeaganBGCohenRDSerious infections and mortality in association with therapies for Crohn’s disease: TREAT registryClin Gastroenterol Hepatol2006662163016678077
   PubMed Web of Science ®Google Scholar
• D’HaensGColombelJFHommesDWCorticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE RegistryGastroenterology2008134Supp1A-140
   Google Scholar
• FordACPeyrin-BirouletLOpportunistic infections with anti-tumor necrosis factor alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trialsAm J Gastroenterol20131081268127623649185
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoL-LBlankMAJohannsJGuzzoCUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med20123671519152823075178
   PubMed Web of Science ®Google Scholar
• BensonJMPerittDScallonBJDiscovery and mechanism of ustekinumab a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disordersMAbs2011353554522123062
   PubMed Web of Science ®Google Scholar
• LeimanDALichtensteinGRTherapy of inflammatory bowel disease: what to expect in the next decadeCurr Opin201430385390
   Google Scholar
• SandbornWJColombelJFEnnsRNatalizumab induction and maintenance therapy for Crohn’s diseaseN Engl J Med20053531912192516267322
   PubMed Web of Science ®Google Scholar
• TarganSRFeaganBGFedorackRNNatalizumab for the treatment of active Crohn’s disease: results of the ENCORE trialsGastroenterology20071321672168317484865
   PubMed Web of Science ®Google Scholar
• CliffordDBDe LucaASimpsonDMArendtGNathANatalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesLancet Neurol2010943844620298967
   PubMed Web of Science ®Google Scholar
• RaineTVedolizumab for inflammatory bowel disease: changing the game, or more of the same?United European Gastroenterol J201425333334
   Web of Science ®Google Scholar
• FeaganBGRutgeertsPBruceEVedolizumab as induction and maintenance therapy for ulcerative colitisN Engl J Med201336969970923964932
   PubMed Web of Science ®Google Scholar
• SandbornWJBrianGFeaganBGVedolizumab as induction and maintenance therapy for Crohn’s diseaseN Engl J Med201336971172123964933
   PubMed Web of Science ®Google Scholar
• SandsBEFeaganBGRutgeertsPEffects of vedolizumab induction for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failedGastroenterology201414761862724859203
   PubMed Web of Science ®Google Scholar
• LeungYGeddesMStorekJPanaccioneRBeckPLHematopoietic cell transplantation for Crohn’s disease: is it time?World J Gastroenterol2006126665667317075981
   PubMed Web of Science ®Google Scholar
• Martínez-MontielMPGómez GómezGJFloresAITherapy with stem cells in inflammatory bowel diseaseWorld J Gastroenterol2014201211122724574796
   PubMed Web of Science ®Google Scholar
• HawkeyCAllezMArdizzoneSClinical and endoscopic improvement following hematopoietic stem cell transplantation in the ASTIC trialJ Crohns Colitis20137S4
   Google Scholar
• ForbesGMSturmMJLeongRWSparrowMPSegarajasingamDA Phase 2 study of allogenic mesenchymal stromal cells for luminal Crohn’s disease refractory to biological therapyClin Gastroenterol Hepatol201412647123872668
   PubMed Web of Science ®Google Scholar
• LaluMMMcIntyreLPuglieseCFergusonDWinstonBWMarshallJCSafety of stromal cells (SafeCell): a systematic review and meta-analysis of clinical trialsPLoS One20127e7559
   Web of Science ®Google Scholar